Intas Pharmaceuticals Ltd - Company Profile
Powered by
All the data and insights you need on Intas Pharmaceuticals Ltd in one report.
- Save hours of research time and resources with
our up-to-date Intas Pharmaceuticals Ltd Strategy Report
- Understand Intas Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and commercializes pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitriptyline, erythropoietin, filgrastim, follicle-stimulating hormone (FSH), rituximab, ampicillin, albendazole, benazepril, and carprofen, among others. It also develops recombinant DNA protein (rDNA) products and plasma-derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma-derived product-based therapies. It has formulation manufacturing facilities and active pharmaceutical ingredients (API) and intermediate facilities in India. The company markets products through an internal sales force and a network of distributors worldwide. Intas is headquartered in Ahmedabad, Gujarat, India.
Intas Pharmaceuticals Ltd premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Therapy Areas: | Service: | Aspasweet |
Cardiovascular | Contract Manufacturing | Selgin |
Diabetology | Axepta | |
XYZ | XYZ | |
XYZ | XYZ | |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | New Products/Services | In June, the company launched TOFATAS, Tofacitinib Ointment 2% w/w to treat patients with mild to moderate Atopic Dermatitis (AD) in patients 18 years and above. |
2022 | Contracts/Agreements | In April, the company entered into a research collaboration with Comera Life Sciences, Inc. to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. |
2021 | Contracts/Agreements | In September, the company and Arecor Therapeutics entered into a formulation agreement to use Arecor's proprietary formulation technology platform, Arestat. |
Competitor Comparison
Key Parameters | Intas Pharmaceuticals Ltd | Lupin Ltd | Torrent Pharmaceuticals Ltd | Adline Chem Lab Ltd | Allied Chemicals and Pharmaceuticals Pvt Ltd |
---|---|---|---|---|---|
Headquarters | India | India | India | India | India |
City | Ahmedabad | Mumbai | Ahmedabad | Ahmedabad | New Delhi |
State/Province | Gujarat | Maharashtra | Gujarat | Gujarat | Delhi |
No. of Employees | - | 18,971 | 13,573 | 27 | - |
Entity Type | Private | Public | Public | Public | Private |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Binish Hasmukh Chudgar | Vice Chairman; Managing Director | Executive Board | 2016 | - |
Nimish Hasmukhbhai Chudgar | Chief Executive Officer; Director; Managing Director | Executive Board | 2016 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer